Formulation and in vitro characterization of cefpodoxime proxetil gastroretentive microballoons

DARU, Journal of Pharmaceutical Sciences

Volumn 19, Issue 1, 2011, Pages 33-40

  Sharma, A K ^a   Keservani, R K ^a   Dadarwal, S C ^b   Choudhary, Y L ^c   Ramteke, S ^a  

^a Rajiv Gandhi Proudyogiki Vishwavidyalaya   (India)

^b UNIVERSITY OF DELHI   (India)

^c JAIPUR NATIONAL UNIVERSITY   (India)

Author keywords

Differential scanning calorimetry; Floating drug delivery system (FDDS); Microparticulate carriers; Solvent evaporation and diffusion method

Indexed keywords

CEFPODOXIME PROXETIL; ETHYL CELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; MICROSPHERE; POLYMER; SOLVENT;

ARTICLE; CHEMICAL REACTION KINETICS; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG RETENTION; EVAPORATION; IN VITRO STUDY; MOLECULAR WEIGHT; PARTICLE SIZE; PROCESS OPTIMIZATION; SURFACE PROPERTY;

EID: 79953285472     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Moes AJ. Gastroretentive dosage forms. Crit. Rev. Ther. Drug Carr. Syst. 1993; 10: 143-195.
2. Deshpande AA, Rhodes CT, Shah NH, Malick AW. Controlled-release drug delivery systems forprolonged gastric residence: an overview. Drug Dev. Ind. Pharm. 1996; 22:531-539.
3. Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Crit. Rev. Ther. Drug Carr. Syst. 1998; 15: 243-284.
4. Yuasa H, Takashima Y, Kanaya Y. Studies on the development of intragastric floating and sustained release preparation: I. Application of calcium silicate as a floating carrier. Chem.Pharm. Bull. 1996; 44:1361-1366.
5. Rouge N, Cole ET, Doelker E, and Buri P. Buoyancy and drug release patterns of floating minitablets containing piretanide and atenolol as model drugs. Pharm. Dev. Technol.1998; 3: 73- 84.
6. Lee JH, Park TG, Choi HK. Development of oral drug delivery system using floating microspheres. J. Microencapsul.1999;16: 715-729.
7. Tripathi G, Singh S. Formulation and In Vitro evaluation of pH sensitive oil entrapped polymeric blended gellan gum buoyant beads of clarithromycin, DARU 2010;18: 247-253.
8. Akiyama Y, Nagahara N, Kashihara T, Hirai S, Toguchi H. In vitro and in vivo evaluation of mucoadhesive microspheres prepared for the gastrointestinal tract using polyglycerol esters of fatty acids and a poly (acrylic acid) derivative. Pharm. Res. 1995; 12: 397-405.
9. Groning R, Berntgen M, Georgarakis M. Acyclovir serum concentrations following peroral administration of magnetic depot tablets and the influence of extracoporeal magnets to control gastrointestinal transit. Eur. J. Pharm. Biopharm. 1998; 46: 285-291.
10. Fix JA, Cargill R, Engle K. Controlled gastric emptying: Part 3. Gastric residence time of a nondisinte grating geometric shape in human volunteers. Pharm. Res. 1993; 10:1087-1089.
11. Park K. Enzyme-digestible swelling hydrogels as platforms for long-term oral drug delivery: synthesis and characterization. Biomaterials. 1988; 9: 435-441.
12. Kawashima Y, Niwa T, Takeuchi H, Hino T, Itoh Y Hollow microspheres for use as a floating controlled drug delivery system in the stomach. J. Pharm. Sei. 1992; 81:135-140.
13. Whitehead L, Fella JT, Colletta JH, Sharma HL, Smith AM. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J. Control Release. 1998; 55: 3-12.
14. Borin T A review of the pharmacokinetics of cefpodoxime proxetil. Drugs. 1991; 42:13-21.
15. Hamamura T, Kusai A, Nishimura K. Gel formation of cefpodoxime proxetil. S.T.P. Pharm. Sei. 1995; 5: 324-331.
16. Hamamura T, Ohtani T, Kusai A, Nishimura K. Unusual dissolution behavior of cefpodoxime proxetil: effect of pH and ionic factors. S.T.P. Pharm. Sei. 1995; 5: 332-338.
17. Hamamura T, Terashima H, Ohtani T, et al. Decrease in dissolution of cefpodoxime proxetil tablets by gel formation and its improvement. Yakuzaigaku. 1995; 55: 175-182.
18. Crauste-Manciet S, Huneau JF, Decroix MO, Tome D, Chaumeil JC. Cefpodoxime proxetil esterase activity in rabbit small intestine: role in the partial cefpodoxime absorption. Int. J. Pharm. 1997; 149: 241-249.
19. Kakumanu VK, Arora V, Bansal AK. Investigation of factors responsible for low oral bioavailability of cefpodoxime proxetil. Int. J. Pharm. 2006; 317:155-160.
20. Hughes GS, Heald DL, Barker KB, et al. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin. Pharmacol. Ther. 1989; 46: 674-85.
21. Streubel A, Siepmann J, Bodmeier R. Multiple unit gastroretentive drug delivery systems: a new preparation method for low density microparticles. J. Microencapsul. 2003; 20: 329-347.
22. US Pharmacopoeia XXVI. US Pharmacopoeial Convention, Rockville, MD, 2003:378-380.
23. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur. J. Pharm. Sei. 2001; 13:123-133.
24. Wagner JG. Interpretation of percent dissolved-time plots derived from in vitro testing of conventional tablets and capsules. J. Pharm. Sei. 1969; 58: 1253-1257.
25. Schefter E, Higuchi T. Dissolution behavior of crystalline solvated and non-solvated forms of some pharmaceuticals. J. Pharm. Sei. 1963; 52: 781-791.
26. Kawashima Y, Iwamoto T, Niwa T, Takeuchi H, Hiño T. Role of the solvent-diffusion-rate modifier in a new emulsion solvent diffusion method for preparation of ketoprofen microspheres.Microencap-sul. 1993; 10:329-340.
27. Reddy BP, Dorle AK, Krishna DK. Albumin microspheres: effect of process variables on the distribution and in vitro release, Drug Dev. Ind. Pharm. 1990; 16:1781-1803.
28. Ishizaka T. Preparation of egg albumin microspheres and microcapsules, J. Pharm. Sei. 1981; 70:358-361.
29. Guiziou B, Amstrong DJ, Elliot PNC, Ford JL. Rostron C. Investigation of in-vitro release characteristics of NSAID-loaded polylactic acid microspheres, J. Microencapsul. 1996; 13:701-708.